USD10
KYTX Shares
About Kyverna TherapeuticsKyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
USD10
KYTX Shares
About Kyverna TherapeuticsKyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Stats
TRADING WINDOW
Closed
OPENS AT
Not enough data
MARKET CAP
$527.17M
OPEN PRICE
$8.57
LOW (1Y)
$1.78
HIGH (1Y)
$13.67
LOW (24H)
$8.50
HIGH (24H)
$9.18
VOLUME (24H)
$757.06K
8.36%
Price history
Time | Price | Change |
|---|---|---|
Today | $8.57 | |
1 Day | $8.87 | |
1 Week | $7.99 | |
1 Month | $8.50 | |
1 Year | $1.91 |
Past performance is not a reliable indicator of future results.
Discover more
Popular cryptocurrencies
Popular price predictions
Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.
